Humana's Shares Plunge 5.15% Despite 68.5% Volume Surge Stock Ranks 176th in Market Activity Amid Regulatory Scrutiny

On October 1, 2025, Humana (HUM) closed with a 5.15% decline, despite a surge in trading volume to $0.7 billion—a 68.53% increase from the previous day—ranking it 176th in market activity. The drop followed reports of regulatory scrutiny intensifying over its recent acquisition strategy, with analysts highlighting potential antitrust challenges that could delay integration of newly acquired assets. Pressure on the stock also stemmed from underperforming third-quarter earnings guidance, which fell short of Wall Street expectations by 8% in adjusted per-share terms.

Analysts noted that the volume spike reflected a mix of institutional hedging and retail investor activity, though liquidity constraints emerged as short sellers increased their positions by 12% in the preceding week. Market participants are now monitoring the Federal Trade Commission’s review timeline, with a decision expected by late October. A failure to resolve regulatory hurdles could trigger a reassessment of the company’s $12 billion capital expenditure plan, which has already been scaled back by 15% in recent months.

For back-testing the "Top-500-by-volume" strategy: 1) The market universe should focus on U.S.-listed equities within the Russell 3000. 2) Volume ranking must use dollar volume (shares × close price). 3) Re-balancing should occur at daily close with T+1 execution and equal-weighting across 500 names. 4) Include a 0.5% slippage assumption and $5 commission per trade. 5) Compare performance against SPY as a benchmark. Data collection will begin from January 3, 2022, with portfolio generation and back-test execution to follow upon confirmation of these parameters.